Payment overview · 2025
General Payments
$186.67
7 reported records · 3 companies
Healthcare provider profile · identity verified
Dania M Verdecia, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · MIAMI, FL · NPI 1003042581
Verified facts
What the public records show
CMS Open Payments records show Dania M Verdecia, ARNP received $186.67 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 77.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $144.59 | 77.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.08 | 12.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.00 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.67 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $144.59 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $6.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 102 |
| Losartan Potassium | Losartan Potassium | 202 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 62 |
| Omeprazole | Omeprazole | 194 | 57 |
| Prednisone | Prednisone | 178 | 117 |
| Azithromycin | Azithromycin | 165 | 113 |
| Fenofibrate | Fenofibrate | 162 | 56 |
| Gabapentin | Gabapentin | 156 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 53 |
| Atenolol | Atenolol | 138 | 45 |
| Metformin Hcl | Metformin Hcl | 133 | 55 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 132 | 40 |
| Lorazepam | Lorazepam | 125 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 43 |
| Famotidine | Famotidine | 119 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 31 |
| Alprazolam | Alprazolam | 108 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 29 |
| Montelukast Sodium | Montelukast Sodium | 91 | 23 |
| Mirtazapine | Mirtazapine | 88 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 86 | 27 |
| Carvedilol | Carvedilol | 85 | 32 |
| Furosemide | Furosemide | 84 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 26 |
| Eliquis | Apixaban | 83 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 73 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 25 |
| Synthroid | Levothyroxine Sodium | 63 | 13 |
| Levofloxacin | Levofloxacin | 62 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 20 |
| Ozempic | Semaglutide | 58 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 19 |
| Folic Acid | Folic Acid | 51 | 13 |
| Temazepam | Temazepam | 51 | 12 |
| Latanoprost | Latanoprost | 49 | 14 |
| Lisinopril | Lisinopril | 49 | 21 |
| Simvastatin | Simvastatin | 48 | 17 |
| Potassium Chloride | Potassium Chloride | 46 | 15 |
| Valsartan | Valsartan | 45 | 15 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Mupirocin | Mupirocin | 38 | 22 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Repaglinide | Repaglinide | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Clonazepam | Clonazepam | 35 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Benzonatate | Benzonatate | 34 | 26 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | 14 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | 12 |
| Ibuprofen | Ibuprofen | 31 | 13 |
| Meloxicam | Meloxicam | 31 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Naproxen | Naproxen | 27 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 20 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Tadalafil | Tadalafil | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | 11 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Mometasone Furoate | Mometasone Furoate | 20 | 12 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.67 · 7 records | Amgen Inc. | JARDIANCE, OTEZLA, REPATHA, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error